Skip to main content

Advertisement

Table 3 Net and incremental benefits from the government use licenses, comparing public health expenditure prior to and after the government use licenses

From: Government use licenses in Thailand: an assessment of the health and economic impacts

Drugs Treatment No of patients increased access to drug (%) Increased productivity (Million USD) Health expenditure (Million USD) Net Benefit (Million USD) Incremental Benefit (Million USD) (%)
EFV 1st line ARV 17,959 (21.3%) 309 97 212 67.0 (50.6%)
NVP    301 156 145  
LPV/r 2nd line ARV 3,421 (4.0%) 8.6 6.9 1.7 2.3 (1.7%)
IDV/r    8.6 9.2 -0.6  
Clopidogrel+ASA 2nd prevention of ischemic events 40,947 (48.7%) 870.6 0.9 869.7 5.7 (4.3%)
ASA only    864.1 0.1 864.0  
Letrozole Breast Cancer Hormone therapy 8,916 (10.6%) 343 2 341 12.0 (9.1%)
Tamoxifen    332 3 329  
Docetaxel Breast Cancer Chemo therapy 5,958 (7.1%) 14.6 1.3 13.3 12.5 (9.5%)
Paclitaxel    11.1 10.3 0.8  
Docetaxel Lung Cancer Chemo therapy 4,855 (5.8%) 5.6 0.8 4.8 25.7 (19.4%)
Pemetrexed    5.6 26.5 -20.9  
Erlotinib Lung Cancer Chemo therapy 256 (0.3%) 0.3 0.6 -0.3 -*
Gifitinib    N/A N/A N/A  
Imatinib CML Chemo therapy 1,293 (1.5%) 4.1 -** 4.1 7.2 (5.4%)
  GIST Chemo therapy 553 (0.7%) 3.1 -** 3.1  
Total 84,158 (100%)     132.4 (100%)
  1. * Erlotinib: no data available to assess the incremental benefit
  2. ** Imatinib: no data on cost of drug as patients receive access to the drug free under GIPAP